Literature DB >> 16198295

The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.

Thomas B Thompson1, Thomas F Lerch, Robert W Cook, Teresa K Woodruff, Theodore S Jardetzky.   

Abstract

TGF-beta ligands stimulate diverse cellular differentiation and growth responses by signaling through type I and II receptors. Ligand antagonists, such as follistatin, block signaling and are essential regulators of physiological responses. Here we report the structure of activin A, a TGF-beta ligand, bound to the high-affinity antagonist follistatin. Two follistatin molecules encircle activin, neutralizing the ligand by burying one-third of its residues and its receptor binding sites. Previous studies have suggested that type I receptor binding would not be blocked by follistatin, but the crystal structure reveals that the follistatin N-terminal domain has an unexpected fold that mimics a universal type I receptor motif and occupies this receptor binding site. The formation of follistatin:BMP:type I receptor complexes can be explained by the stoichiometric and geometric arrangement of the activin:follistatin complex. The mode of ligand binding by follistatin has important implications for its ability to neutralize homo- and heterodimeric ligands of this growth factor family.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198295     DOI: 10.1016/j.devcel.2005.09.008

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  110 in total

Review 1.  Anti-inflammatory defense mechanisms of Entamoeba histolytica.

Authors:  Raúl Silva-García; Guadalupe Rico-Rosillo
Journal:  Inflamm Res       Date:  2010-10-12       Impact factor: 4.575

2.  Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts.

Authors:  Darcie D Seachrist; Emhonta Johnson; Christianne Magee; Colin M Clay; James K Graham; D N Rao Veeramachaneni; Ruth A Keri
Journal:  Biol Reprod       Date:  2012-08-23       Impact factor: 4.285

3.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

Review 4.  The structures that underlie normal reproductive function.

Authors:  Thomas F Lerch; Min Xu; Theodore S Jardetzky; Kelly E Mayo; Ishwar Radhakrishnan; Ralph Kazer; Lonnie D Shea; Teresa K Woodruff
Journal:  Mol Cell Endocrinol       Date:  2006-11-30       Impact factor: 4.102

Review 5.  Spemann's organizer and self-regulation in amphibian embryos.

Authors:  Edward M De Robertis
Journal:  Nat Rev Mol Cell Biol       Date:  2006-04       Impact factor: 94.444

Review 6.  The DAN family: modulators of TGF-β signaling and beyond.

Authors:  Kristof Nolan; Thomas B Thompson
Journal:  Protein Sci       Date:  2014-06-02       Impact factor: 6.725

7.  Structure of Gremlin-2 in Complex with GDF5 Gives Insight into DAN-Family-Mediated BMP Antagonism.

Authors:  Kristof Nolan; Chandramohan Kattamuri; Scott A Rankin; Randy J Read; Aaron M Zorn; Thomas B Thompson
Journal:  Cell Rep       Date:  2016-08-11       Impact factor: 9.423

Review 8.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 9.  Regulation of the ovarian reserve by members of the transforming growth factor beta family.

Authors:  Stephanie A Pangas
Journal:  Mol Reprod Dev       Date:  2012-09-11       Impact factor: 2.609

10.  Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers.

Authors:  Chandramohan Kattamuri; David M Luedeke; Kristof Nolan; Scott A Rankin; Kenneth D Greis; Aaron M Zorn; Thomas B Thompson
Journal:  J Mol Biol       Date:  2012-10-09       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.